The drug giants moved in near-perfect synchronicity, raising prices for their top-selling arthritis treatments as though they were opposite-corner gas stations bumping up the price of unleaded.

On Jan. 3, 2013, AbbVie (ABBV) hiked the price of Humira, its blockbuster biologic drug for arthritis and related conditions, by 6.9 percent. A day later, Amgen (AMGN) followed with an identical increase for Enbrel, another biologic used to treat similar patients. The pattern repeated 10 more times between 2014 and early 2018. In every instance, prices of both drugs jumped by nearly the same percentage, usually within days of each other, topping out at the exact same amount, $63,363 per year, according to a STAT analysis of pricing data.

Unlock this article by subscribing to STAT Plus and enjoy your first 30 days free!

GET STARTED

What is it?

STAT Plus is STAT's premium subscription service for in-depth biotech, pharma, policy, and life science coverage and analysis. Our award-winning team covers news on Wall Street, policy developments in Washington, early science breakthroughs and clinical trial results, and health care disruption in Silicon Valley and beyond.

What's included?

  • Daily reporting and analysis
  • The most comprehensive industry coverage from a powerhouse team of reporters
  • Subscriber-only newsletters
  • Daily newsletters to brief you on the most important industry news of the day
  • Online intelligence briefings
  • Frequent opportunities to engage with veteran beat reporters and industry experts
  • Exclusive industry events
  • Premium access to subscriber-only networking events around the country
  • The best reporters in the industry
  • The most trusted and well-connected newsroom in the health care industry
  • And much more
  • Exclusive interviews with industry leaders, profiles, and premium tools, like our CRISPR Trackr.

Leave a Comment

Please enter your name.
Please enter a comment.

  • One must admire the strategies while vilifying the outcomes. Pharma ups the costs in anticipation of Congress stepping in sooner or later. THEN Pharma can appear to be playing ball by dropping their prices…right back to the previous exorbitant level…and ‘everyone’ is happy…except the consumer, of course.

  • Azar is the fox in charge of the hen house. Any idiot could have predicted that putting one of the criminals in charge, would have increased the looting. What we really need it to revisit and enforce the laws we used to have, regarding price fixing, price gouging, false claims, and monopolies. Pharma paid off our politicians and saw to it that congress took away the funding for enforcement or the remaining laws. The research that helped create these drugs in the first place was funded by the American people. What we have here is profiteering. The public pays for the research, and they privatize the profits. These pharma execs are worse than the Mafia!

    • Yes, the fox is guarding the hen house. Today in the FDA’s announcement about its fight against youth smoking, Dr. Gottlieb said Alex Azar shares his “deep commitment to protecting the health of our nation’s children.” Well, tell that to children and young people with type 1 diabetes (and their parents) who cannot afford insulin. I guess his commitment to children’s health has certain limits, which have a lot to do with which corporation profits from their illnesses. As I recall, he has been against the ACA and advocated its repeal. How is that showing his commitment to children’s health? It boggles the mind.

  • Hmmmmmm. Where have we heard this before?? Let’s see….INSULIN. A drug that was discovered in the 1930s and whose patent was given free to academia. Lockstep 700% price increases for a life-saving drug, vials going from $23 in late 90s to $300+ today, people dying as they try to ration it. And Alex Azar, now HHS head, was at the helm of Lilly when this was happening.

Sign up for our Daily Recap newsletter

A roundup of STAT’s top stories of the day in science and medicine

Privacy Policy